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Treatment Dear Editor,
Allergic diseases are manifested in various forms, such as atopic
dermatitis (AD), bronchial asthma (BA) and allergic rhinitis (AR).
Dermatitis research, such as that on Netherton syndrome, has pro-
gressed to the stage where it is now thought that lesions in the
epithelial barrier predispose people to eczema, and that atopy
might be a secondary disease.1
Filaggrin (FLG) has been known as a natural moisturizing factor
and barrier-related protein. Mutation in the human FLG gene has
been reported to be the most signiﬁcant risk factor for AD. It has
also been demonstrated that FLG gene mutations increased the
risk of bronchial asthma in patients with atopic dermatitis. These
ﬁndings have brought a breakthrough, where AD may be now
considered as a barrier disorder disease.2
In contrast, FLG in the nose has not been well studied directly,
although there are abundant mentions of FLG in relation to allergic
rhinitis.3 In this study, for the ﬁrst time, we attempted to evaluate
FLG expression in human nasal mucosa through real time RT-PCR
and demonstrated those alterations after various stimulations.
Moreover, we also attempted to conﬁrm the immunohistochemical
localization of FLG in nasal mucosa, as presented previously in a
preliminary study.4
Primary human nasal epithelial cells culture was performed in
an air-liquid interface, as described by Gruenert et al.5 Human nasal
epithelial cells were purchased from PromoCell GmbH (Heidelberg,
Germany). The cell suspension of nasal epithelial cells was placed
on a collagen-coated (Cellmatrix Type I-P, Nitta Gelatin, Japan)
membrane ﬁlter (Millicel-CM, Millipore, MA, USA).
Quantitative PCR analysis was performed, as described by
Kinoshita et al.,6 after stimulation of the lipopolysaccharides with
Escherichia coli (LPS, 1 mg/ml), Polyinosinicepolycytidylic acid po-
tassium salt (Poly I: C 1 mg/ml), TNFa (20 ng/ml), and TNFa
(20 ng/ml) þ Poly I: C 1 mg/ml for 24 h, respectively.
The immunohistochemistry studywas performed using biopsies
from three Japanese nonatopic patients. The anti-ﬁlaggrin primary
antibody employed was an afﬁnity-puriﬁed rabbit polyclonal IgG
antibody (1/500 dilution; ab24584; Abcam PLC, Cambridge, UK).
Stainingwas achievedwith aSimple Stainkit (Nichirei, Tokyo, Japan)
and developed with 3, 3-diaminobenzidine tetrahydrochloride
(DAB) and hydrogenperoxide (Nichirei). The sections were counter-
stainedwith hematoxylin. The ethics committee of DokkyoMedical
University Koshigaya Hospital approved the study.Peer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).An unpaired Student t test (2-tailed) or 1-way ANOVA with the
Tukey multiple comparison test was used. P values of less than .05
were regarded as statistically signiﬁcant.
After stimulation of LPS, Poly I: C, TNFa and TNFa þ Poly I: C for
24 h, respectively, FLG expressions were diminished signiﬁcantly
(Fig. 1). We have already demonstrated that LPS and poly I: C
diminish transepithelial resistance (TER), respectively, which may
reﬂect the down-regulation of airway epithelia.7 Measurements
of TER of these conditions will be necessary for direct analysis.
Kim et al.8 reported that TNF-a downregulates FLG expression in
skin. In this study, the effect was maximal after stimulation with
TNFa þ Poly I: C. Poly I: C and TNF-alpha have might have different
mechanisms for the expression of FLG in human nasal mucosa.
We also tried to conﬁrm the localization of FLG in various tissues.
Our immunohistochemical study showed that, FLGwas expressed in
the nose in human nasal epithelial cells of the inferior turbinate, not
only in the stratiﬁed squamous epithelium in the anterior portion,
but also in the pseudo-stratiﬁed ciliated epithelium in the posterior
portion, as well as the maxillary sinus mucosa (Fig. 2).
Palmer et al.,2 Ying et al.9 and De Benedetto10 et al. demonstrated
a lack of FLG expression in the human airway. In contrast to those
previous reports, in this study, for the ﬁrst time, we conﬁrmed
that FLG exists in the human nose through both real time PCR
and immunohistochemical procedures. Under Th2 dominated
circumstances, it has been reported that FLG expression is down-
regulated in vitro.11 From this study, we demonstrated that bacterialFig. 1. Effects of microbial derivatives for ﬁlaggrin expression in primary cultured hu-
man nasal epithelial cells. After stimulation of lipopolysaccharides from E. coli (LPS,
1 mg/ml), Polyinosinicepolycytidylic acid potassium salt (Poly I: C 1 mg/ml),
TNFa(20 ng/ml), TNFa(20 ng/ml) þ Poly I: C 1 mg/ml for 24 h respectively. Each exper-
iment was performed 5 times and representative data was shown. Data shown are the
means ± SDs.
vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 2. Immunohistochemical analysis of ﬁlaggrin was evaluated under a microscope at 100 magniﬁcation. Scale bar: 30 mM. Epidermis (A), oral mucosa (B), anterior portion of
inferior turbinate (stratiﬁed squamous epithelium) (C), posterior portion of inferior turbinate (pseudostratiﬁed ciliated epithelium) (D), maxillary sinus mucosa (E) were demon-
strated ﬁlaggrin positive cells immunohistochemically. Filaggrin positive cells were not detected in bronchial mucosa (F). Non-speciﬁc staining of FLG was observed in a number of
inﬁltrating inﬂammatory cells, as well as in the nucleus and the cell membranes of some epithelial cells.
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mucosa for the ﬁrst time.
Pseudostratiﬁed ciliated columnar epithelium is the main respi-
ratory epithelium in the human upper airway; however, the ante-
rior portion of the inferior turbinate consists of stratiﬁed
squamous epithelium.Weidinger et al.3 reported that nasal biopsies
demonstrated FLG expression only in the cornﬁeld epithelium of
the nasal vestibular lining. It is well recognized that airway ciliated
mucosa has keratin related proteins. In a immunohistochemical
study, we demonstrated that FLG is located in the human nasal
epithelial cells of the inferior turbinate, not only in the stratiﬁed
squamous epithelium in the anterior portion, but also in the pseu-
dostratiﬁed ciliated epithelium in the posterior portion, as well as
in the maxillary sinus mucosa.
In conclusion, for the ﬁrst time, we demonstrated that precise
localization of FLG in human nasal mucosa and TLR-3 and -4
signaling altered the amount of FLG gene expression in human
nasal mucosa. A possible new therapeutic strategy to regulate
atopic dermatitis through upregulating expression has been re-
ported.12 On the other hand, from the viewpoint of our study, thiscontrol has not been demonstrated in the airway at al. It may be ex-
pected that further studies including western blotting will lead to a
ﬁx for the epithelial barrier in order to treat and prevent AR as a
barrier disorder.Conﬂict of interest
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